Compare Stocks: ALPS, RNA, IVVD, and CYPH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALPS ALPS Group Inc Ordinary Share	$0.38	$0.44	$0.23 ▼ $15.00	$63.23M	-0.1	84,356 shs	48,642 shs
CYPH Cypherpunk Technologies	$2.42 +6.6%	$0.94	$0.27 ▼ $3.70	$244.62M	0.33	8.50 million shs	16.90 million shs
IVVD Invivyd	$0.83 -1.1%	$0.77	$0.53 ▼ $3.07	$246.12M	0.81	4.21 million shs	1.96 million shs
RNA Avidity Biosciences	$14.19 -2.8%	$12.73	$11.13 ▼ $16.77	$249.74M	N/A	151,608 shs	167,785 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALPS ALPS Group Inc Ordinary Share	0.00%	-1.27%	-5.59%	-46.48%	+37,999,900.00%
CYPH Cypherpunk Technologies	+6.61%	+41.52%	+230.15%	+366.46%	+734.77%
IVVD Invivyd	-1.08%	-14.36%	+36.66%	-19.81%	-20.58%
RNA Avidity Biosciences	-2.81%	+4.03%	+20.87%	+20.25%	-70.18%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALPS ALPS Group Inc Ordinary Share	$0.38	$0.44	$0.23 ▼ $15.00	$63.23M	-0.1	84,356 shs	48,642 shs
CYPH Cypherpunk Technologies	$2.42 +6.6%	$0.94	$0.27 ▼ $3.70	$244.62M	0.33	8.50 million shs	16.90 million shs
IVVD Invivyd	$0.83 -1.1%	$0.77	$0.53 ▼ $3.07	$246.12M	0.81	4.21 million shs	1.96 million shs
RNA Avidity Biosciences	$14.19 -2.8%	$12.73	$11.13 ▼ $16.77	$249.74M	N/A	151,608 shs	167,785 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALPS ALPS Group Inc Ordinary Share	0.00%	-1.27%	-5.59%	-46.48%	+37,999,900.00%
CYPH Cypherpunk Technologies	+6.61%	+41.52%	+230.15%	+366.46%	+734.77%
IVVD Invivyd	-1.08%	-14.36%	+36.66%	-19.81%	-20.58%
RNA Avidity Biosciences	-2.81%	+4.03%	+20.87%	+20.25%	-70.18%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALPS ALPS Group Inc Ordinary Share	1.00	Sell	N/A	N/A
CYPH Cypherpunk Technologies	2.00	Hold	$1.60	-33.88% Downside
IVVD Invivyd	2.33	Hold	$8.00	868.52% Upside
RNA Avidity Biosciences	2.29	Hold	$63.85	349.94% Upside

Current Analyst Ratings Breakdown

Latest ALPS, RNA, IVVD, and CYPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	CYPH Cypherpunk Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$1.60
8/27/2026	IVVD Invivyd	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/24/2026	IVVD Invivyd	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/19/2026	CYPH Cypherpunk Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$0.90 ➝ $1.60
8/18/2026	IVVD Invivyd	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	CYPH Cypherpunk Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	RNA Avidity Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
8/6/2026	RNA Avidity Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$25.00
8/3/2026	RNA Avidity Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E-) ➝ Sell (E)
7/31/2026	CYPH Cypherpunk Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/24/2026	IVVD Invivyd	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALPS ALPS Group Inc Ordinary Share	$4.86M	13.01	N/A	N/A	($3.10) per share	-0.12
CYPH Cypherpunk Technologies	N/A	N/A	N/A	N/A	$1.29 per share	N/A
IVVD Invivyd	$53.43M	4.56	N/A	N/A	$0.61 per share	1.35
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	$12.54 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALPS ALPS Group Inc Ordinary Share	-$2.01M	$0.33	1.15	N/A	N/A	N/A	N/A	N/A	N/A
CYPH Cypherpunk Technologies	$4.82M	$0.56	4.32	N/A	N/A	N/A	-20.76%	-19.48%	N/A
IVVD Invivyd	-$52.49M	-$0.33	N/A	N/A	N/A	-183.90%	-59.73%	-48.97%	11/5/2026 (Estimated)
RNA Avidity Biosciences	N/A	-$2.15	N/A	N/A	N/A	N/A	N/A	N/A	11/12/2026 (Estimated)

Latest ALPS, RNA, IVVD, and CYPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	IVVD Invivyd	-$0.1067	-$0.14	-$0.0333	-$0.14	$14.40 million	$14.29 million
8/13/2026	Q2 2026	RNA Avidity Biosciences	-$1.42	-$1.18	+$0.24	-$1.18	$0.67 million	$3.00 million
8/12/2026	Q2 2026	CYPH Cypherpunk Technologies	N/A	$0.18	N/A	$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALPS ALPS Group Inc Ordinary Share	N/A	N/A	N/A	N/A	N/A
CYPH Cypherpunk Technologies	N/A	N/A	N/A	N/A	N/A
IVVD Invivyd	N/A	N/A	N/A	N/A	N/A
RNA Avidity Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALPS ALPS Group Inc Ordinary Share	N/A	0.36	0.27
CYPH Cypherpunk Technologies	N/A	79.19	79.19
IVVD Invivyd	N/A	5.87	5.87
RNA Avidity Biosciences	N/A	8.73	8.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALPS ALPS Group Inc Ordinary Share	27.90%
CYPH Cypherpunk Technologies	30.46%
IVVD Invivyd	70.36%
RNA Avidity Biosciences	N/A

Insider Ownership

Company	Insider Ownership
ALPS ALPS Group Inc Ordinary Share	25.52%
CYPH Cypherpunk Technologies	3.50%
IVVD Invivyd	12.25%
RNA Avidity Biosciences	3.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALPS ALPS Group Inc Ordinary Share	N/A	166.40 million	123.94 million	N/A
CYPH Cypherpunk Technologies	40	107.76 million	103.99 million	Optionable
IVVD Invivyd	100	294.76 million	258.65 million	Optionable
RNA Avidity Biosciences	190	17.11 million	16.45 million	Optionable

ALPS, RNA, IVVD, and CYPH Headlines

Recent News About These Companies

Atrium Therapeutics to Participate in Upcoming Investor Conferences

September 2 at 8:00 AM | prnewswire.com

Avidity Biosciences (NASDAQ:RNA) Stock Crosses Below Two Hundred Day Moving Average - Here's Why

September 2 at 2:42 AM | americanbankingnews.com

Avidity Biosciences (NASDAQ:RNA) Shares Cross Below 200 Day Moving Average - Time to Sell?

September 2 at 2:39 AM | marketbeat.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Rating of "Hold" from Brokerages

August 30, 2026 | americanbankingnews.com

Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Recommendation of "Hold" from Analysts

August 25, 2026 | marketbeat.com

Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 20, 2026 | prnewswire.com

HC Wainwright Issues Optimistic Forecast for RNA Earnings

August 18, 2026 | marketbeat.com

Avidity Biosciences' (RNA) Buy Rating Reaffirmed at HC Wainwright

August 14, 2026 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Issues Earnings Results

August 13, 2026 | marketbeat.com

Atrium Therapeutics Reports Second Quarter 2026 Financial Results

August 13, 2026 | prnewswire.com

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

August 13, 2026 | prnewswire.com

Q3 Earnings Estimate for RNA Issued By HC Wainwright

August 10, 2026 | marketbeat.com

Avidity Biosciences (NASDAQ:RNA) Now Covered by HC Wainwright

August 6, 2026 | marketbeat.com

Avidity Biosciences (RNA) Expected to Announce Quarterly Earnings on Thursday

August 6, 2026 | marketbeat.com

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 20, 2026 | prnewswire.com

Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome

July 14, 2026 | prnewswire.com

Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

June 23, 2026 | prnewswire.com

Novartis Trial Wins Highlight Rhapsido And RNA FSHD Potential For Growth

June 14, 2026 | finance.yahoo.com

Novartis RNA drug acquired in $12B Avidity deal notches a trial win

June 12, 2026 | biopharmadive.comB

Atrium Therapeutics Reports First Quarter 2026 Financial Results

May 14, 2026 | prnewswire.com

Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

April 23, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ALPS, RNA, IVVD, and CYPH Company Descriptions

ALPS Group Inc Ordinary Share NASDAQ:ALPS

$0.38 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

ALPS Group Inc is a fully integrated platform encompassing biotechnology research, medical, and wellness services specializing in predictive, precision and preventive health management. It aims to provide its clientele with access to DNA and mRNA sequencing, cellular therapy, as well as wellness and anti-aging products and services.

Cypherpunk Technologies NASDAQ:CYPH

$2.42 +0.15 (+6.61%)

As of 09/4/2026 04:00 PM Eastern

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Invivyd NASDAQ:IVVD

$0.83 -0.01 (-1.08%)

As of 09/4/2026 04:00 PM Eastern

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Avidity Biosciences NASDAQ:RNA

$14.19 -0.41 (-2.81%)

As of 09/4/2026 04:00 PM Eastern

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALPS, RNA, IVVD, and CYPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALPS, RNA, IVVD, and CYPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALPS, RNA, IVVD, and CYPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALPS, RNA, IVVD, and CYPH Company Descriptions

ALPS Group Inc Ordinary Share NASDAQ:ALPS

Cypherpunk Technologies NASDAQ:CYPH

Invivyd NASDAQ:IVVD

Avidity Biosciences NASDAQ:RNA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALPS, RNA, IVVD, and CYPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALPS, RNA, IVVD, and CYPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALPS, RNA, IVVD, and CYPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALPS, RNA, IVVD, and CYPH Company Descriptions

ALPS Group Inc Ordinary Share NASDAQ:ALPS

Cypherpunk Technologies NASDAQ:CYPH

Invivyd NASDAQ:IVVD

Avidity Biosciences NASDAQ:RNA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools